Crossmark Global Holdings Inc. Cuts Holdings in IDEXX Laboratories, Inc. (IDXX)
Crossmark Global Holdings Inc. lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 25.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,520 shares of the company’s stock after selling 4,223 shares during the period. Crossmark Global Holdings Inc.’s holdings in IDEXX Laboratories were worth $1,958,000 at the end of the most recent reporting period.
A number of other hedge funds also recently added to or reduced their stakes in the business. National Asset Management Inc. grew its stake in IDEXX Laboratories by 2.1% in the 2nd quarter. National Asset Management Inc. now owns 2,051 shares of the company’s stock worth $332,000 after buying an additional 42 shares in the last quarter. Thrivent Financial For Lutherans grew its stake in IDEXX Laboratories by 3.1% in the 2nd quarter. Thrivent Financial For Lutherans now owns 3,340 shares of the company’s stock worth $539,000 after buying an additional 100 shares in the last quarter. LS Investment Advisors LLC grew its stake in IDEXX Laboratories by 8.2% in the 3rd quarter. LS Investment Advisors LLC now owns 4,846 shares of the company’s stock worth $754,000 after buying an additional 368 shares in the last quarter. Norinchukin Bank The grew its stake in IDEXX Laboratories by 6.2% in the 3rd quarter. Norinchukin Bank The now owns 6,495 shares of the company’s stock worth $1,010,000 after buying an additional 379 shares in the last quarter. Finally, Cubist Systematic Strategies LLC grew its stake in IDEXX Laboratories by 5.3% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 7,662 shares of the company’s stock worth $1,191,000 after buying an additional 384 shares in the last quarter. 86.50% of the stock is owned by institutional investors and hedge funds.
A number of research firms have commented on IDXX. Piper Jaffray Companies boosted their price target on shares of IDEXX Laboratories to $211.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Bank of America upped their price objective on shares of IDEXX Laboratories from $200.00 to $220.00 and gave the company a “buy” rating in a research note on Friday, February 2nd. BidaskClub raised shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, January 31st. Zacks Investment Research cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $210.00 price objective on shares of IDEXX Laboratories in a research note on Monday, January 29th. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $194.00.
IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Thursday, February 1st. The company reported $0.77 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.04. IDEXX Laboratories had a net margin of 13.36% and a negative return on equity of 432.19%. The company had revenue of $506.00 million during the quarter, compared to analysts’ expectations of $490.51 million. During the same quarter in the prior year, the company earned $0.58 EPS. The firm’s revenue was up 14.2% on a year-over-year basis. analysts forecast that IDEXX Laboratories, Inc. will post 4.09 earnings per share for the current fiscal year.
In other IDEXX Laboratories news, CEO Jonathan W. Ayers sold 18,000 shares of the stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $153.61, for a total transaction of $2,764,980.00. Following the completion of the sale, the chief executive officer now owns 1,064,573 shares of the company’s stock, valued at approximately $163,529,058.53. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bruce L. Claflin purchased 1,000 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were purchased at an average cost of $179.58 per share, with a total value of $179,580.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at $179,580. The disclosure for this purchase can be found here. Insiders sold a total of 104,762 shares of company stock valued at $17,967,464 in the last ninety days. 2.77% of the stock is owned by corporate insiders.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.